Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Dewey

Ophthalmology Colorado Springs, CO Medical Doctor

NPI 1144296922 CMS profile 1107765

2770 N Union Blvd, Suite 200, Colorado Springs, CO 80909

Open in the dashboard

General payments

$245,680

153 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Dewey of Colorado Springs, CO is reported in the CMS Open Payments database as having received $245,680 across 153 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $37,109 16
2024 General $52,009 21
2023 General $40,951 21
2022 General $77,912 33
2021 General $23,396 37
2020 General $6,335 6
2019 General $7,967 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Dewey
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Steven Dewey were reported at $37,109. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Steven Dewey Ophthalmology median Middle half National median
2019 $7,967 $258 $104–$655 $163
2020 $6,335 $126 $45–$321 $114
2021 $23,396 $205 $76–$534 $132
2022 $77,912 $266 $100–$678 $149
2023 $40,951 $308 $117–$745 $160
2024 $52,009 $340 $127–$846 $164
2025 $37,109 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Microsurgical Technology, Inc. $141,768 4 payments
  2. Johnson & Johnson Surgical Vision, Inc. $101,535 123 payments
  3. Ivantis, Inc $1,083 2 payments
  4. Leica Microsystems Inc. $294 5 payments
  5. Alcon Vision LLC $236 6 payments
  6. Johnson & Johnson Vision Care, Inc. $196 2 payments
  7. Bausch & Lomb Americas Inc. $161 2 payments
  8. Allergan Inc. $141 1 payment
  9. RxSight Inc $77 1 payment
  10. New World Medical,Inc. $67 1 payment
  11. Other $122 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $141,768 4 payments
  2. Consulting Fee $87,911 35 payments
  3. Food and Beverage $5,603 93 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,500 1 payment
  5. Travel and Lodging $4,755 18 payments
  6. Education $143 2 payments
Products named General payments · program years 2019–2025
  1. AMO PHACO NEEDLE $44,917 26 payments
  2. Tecnis IOL $40,923 16 payments
  3. One Series Ultra $39,723 16 payments
  4. Tecnis IOL Optics $11,170 3 payments
  5. Whitestar Phacoemulsficiation System $10,933 7 payments
  6. VERITAS Vision System $8,402 24 payments
  7. Ophthalmic Surgical Adjuncts $5,700 3 payments
  8. One Series Ultra IOL Delivery System $5,700 3 payments
  9. Whitestar Signature Pro $3,894 8 payments
  10. Tecnis Simplicity $1,124 9 payments
  11. Other $8,095 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

3,289

Median for Ophthalmology: 891

Drug cost

$119,032

Median for Ophthalmology: $68,233

Branded share of claims

41%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 742 $39,241
Erythromycin Erythromycin Base Brand 1,294 $30,197
Restasis Cyclosporine Brand 27 $25,613
Ketorolac Tromethamine Generic 781 $14,816
Levobunolol Hcl Generic 137 $3,178
Latanoprost Generic 169 $2,212
Fluorometholone Generic 13 $1,555
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 13 $855
Timolol Maleate Generic 88 $617
Dorzolamide Hcl Generic 11 $463

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$239,888

Medicare's payments for the services billed

Medicare patients

721

Average age 76

Services billed

1,723

427 women, 294 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 44%
Diabetes 24%
Ischemic heart disease 21%
Chronic kidney disease 19%
Cancer 14%
Depression 14%
Osteoporosis 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

153 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record